Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas sues Impax over US Flomax patent

This article was originally published in Scrip

Executive Summary

Japan's Astellas Pharmahas filed suit against Impaxin the US District Court for the Northern District of California, alleging infringement related to its generic version of the benign prostatic hyperplasia treatment Flomax (tamsulosin HCl), thus triggering a 30-month stay of approval while the legal challenge is fought. The lawsuit was filed jointly with Boehringer Ingelheim's US subsidiary, which co-markets the product in the US.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts